Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Investments (2016 - 2019)

Lineage Cell Therapeutics' Long-Term Investments history spans 5 years, with the latest figure at $19.0 million for Q4 2019.

  • For Q4 2019, Long-Term Investments fell 6.17% year-over-year to $19.0 million; the TTM value through Dec 2019 reached $19.0 million, down 6.17%, while the annual FY2019 figure was $19.0 million, 6.17% down from the prior year.
  • Long-Term Investments reached $19.0 million in Q4 2019 per LCTX's latest filing, up from $17.7 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $110.8 million in Q3 2017 to a low of $3.5 million in Q3 2016.
  • Average Long-Term Investments over 5 years is $40.4 million, with a median of $29.4 million recorded in 2018.
  • Peak YoY movement for Long-Term Investments: soared 3081.79% in 2017, then crashed 74.48% in 2018.
  • A 5-year view of Long-Term Investments shows it stood at $4.7 million in 2015, then surged by 2040.87% to $100.0 million in 2016, then crashed by 31.8% to $68.2 million in 2017, then plummeted by 70.31% to $20.2 million in 2018, then fell by 6.17% to $19.0 million in 2019.
  • Per Business Quant, the three most recent readings for LCTX's Long-Term Investments are $19.0 million (Q4 2019), $17.7 million (Q3 2019), and $36.5 million (Q2 2019).